Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
-
Published:2021-06
Issue:3
Volume:19
Page:274.e1-274.e16
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Verhaart Saskia Lisa, Abu-Ghanem Yasmin, Mulder Sasja F.ORCID, Oosting SjoukjeORCID, Van Der Veldt AstridORCID, Osanto Susanne, Aarts Maureen J.B., Houtsma Danny, Peters Frank P.J., Groenewegen GerardORCID, Van Herpen Carla M.L., Pronk Loes M., Tascilar Metin, Hamberg PaulORCID, Los Maartje, Vreugdenhil Gerard, Polee Marco, Ten Tije Albert J., Haanen John B.A.G., Bex Axel, van den Eertwegh Alfonsus J.
Reference19 articles.
1. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion;Dong;Nat Med,2002 2. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death;Ishida;EMBO J,1992 3. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010 4. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015 5. Kidney cancer, version 2.2017: Clinical practice guidelines in oncology;Motzer;J Natl Compr Cancer Netw,2017
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|